Main > > >BRAIN CANCER. *

---

DIAG.: Biopsy+TREAT.: Surgery.
USA Approval Date: 2018. 05.24.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 03.08.




DIAG.: Spectroscopic Liquid Biopsy with
AI.
(*) Company; Patents & Web-Site Avai-
lable on Request.
UpDate: 2021. 02.14.




Gamma Stereotactic Radio Surgery (SRS)
System.
USA Approval Date: 2021. 03.10.
(*) Company; TradeMark & Web-Site Avai-
lable on Request.
UpDate: 2021. 03.11.




TREAT.: BevacizuMAb. (BioSimilar)
[GlioBlastoma Multiforme (GBM)]
USA Approval Date: 2017. 09.14.
(*) Company : Amgen.
TradeMark: MVASI.
UpDate: 2018. 06.13.




TREAT.: BevacizuMAb. (Brand)
[GlioBlastoma Multiforme (GBM)]
USA Approval Date: 2009. 05.05.
(*) Company : Genentech.
TradeMark: Avastin.
UpDate: 2018. 06.13.




TREAT.: BevacizuMAb. (Brand)
[GlioBlastoma Multiforme (GBM) Recurrent
USA Approval Date: 2017. 12.05.
(*) Company : Genentech.
TradeMark: Avastin.
UpDate: 2018. 06.13.




TREAT.: BrachyTherapy. (After Surgery)
Description:
BioResorbable & Conformable 3D Collagen
Tile Embedded with Caesium (Cs) Radio-
active Seeds.
USA Approval Date: 2018. 07.06>
>Recurrent Brain Cancers
USA Approval Date: 2020. 01.27>
>Newly Diagnosed Brain Cancers.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 02.08.




TREAT.: Carmustine Implant.
[GlioBlastoma Multiforme (GBM) Recurrent
Adjunct to to Surgery.
USA Approval Date: ?.
(*) Company : Arbor Pharma
TradeMark: Gliadel
Web-Site : gliadel.com/hcp/
UpDate: 2018. 06.13.




TREAT.: Electric Fields.
[GlioBlastoma Multiforme (GBM)]
2nd Generation System.
Newly Diagnosed Glioblastoma
Recurrent Glioblastoma.
JP Approval Date : 2016. 12.19.
USA Approval Date: 2016. 07.13.
(*) Company; Patents; TradeMark & Web-
Sites Available on Request.
UpDate: 2018. 06.13.




TREAT.: Electric Fields.+Temozolomide.
[GlioBlastoma Multiforme (GBM) Newly
Diagnosed].
IL National Reimbursement Date:
2020. 01.21.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 02.09.




TREAT.: Everolimus.
[Tuberous Sclerosis Complex (TSC)-asso-
ciated Subependymal Giant Cell Astrocytoma (SEGA)]
USA Approval Date: ?
(*) Company; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 06.13.




TREAT.: Minimally Invasive Laser Inter-stitial Thermal Therapy (LITT) Tool>
[GlioBlastoma Multiforme (GBM)]
>Favorable 12-Month Outcomes for
Patients Receiving Minimally Invasive
Laser Ablation for Brain Tumors
(*) Company; Patents; TradeMark & Web-
Sites Available on Request.
UpDate: 2020. 04.26.




TREAT.: Surgery.
EU Approval Date: 2017. 04.03.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 06.13.




TREAT.: Surgery. UltraSound (US) Abla-
tion System.
USA Approval Date: 2020. 07.22.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 09.27.




TREAT.: Temozolomide. Brand.
[GlioBlastoma Multiforme (GBM)]
USA Approval Date: ?
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 06.13.




TREAT.: Temozolomide. Generic.
[GlioBlastoma Multiforme (GBM)]
USA Launch Date: 2016. 08.19.
(*) Company: Amerigen Pharmaceuticals
MFG. By: Stason Pharmaceuticals Inc.
UpDate: 2018. 06.13.




TREAT.: Temozolomide. Generic.
[GlioBlastoma Multiforme (GBM)]
USA Approval Date: 2016. 03.29.
(*) Company: Lannett Company Inc.
UpDate: 2018. 06.13.




TREAT.: Temozolomide. Generic.
[GlioBlastoma Multiforme (GBM)]
USA Launch Date: 2016. 07.11.
(*) Company : Mylan NV.
UpDate: 2018. 06.13.


>BRAIN CANCER. *'s products
This section has no products